Skip to content

Vera Therapeutics

US · VERA #2739 by market cap Listed 2021
25.45 -1.30 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.10 Expensive vs history 69th percentile
5-year average 5.98 · #410 of 514 in Biotechnology
P/E ratio -4.76 Expensive vs history 78th percentile
5-year average -8.79 · forward -6.76
P/S ratio 197.68 Expensive vs history 100th percentile
5-year average 1.00 · forward 10.26 · #316 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Vera Therapeutics (VERA) 1.84B -4.31 5.52 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value44.07 Economic moatNone UncertaintyVery High

Trading 73.1% below Morningstar's fair value estimate.

Fair value

Vera Therapeutics Inc receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 36% discount to our quantitative fair value estimate of $44.07 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its gross margin of 67.9%, which falls in the top 10% compared with global peers. This suggests that it will more easily generate cash flow than peers. We believe this is a sign that shares could be cheap.

Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 15.5%, for example, falls in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vera Therapeutics discussion 0 comments

Add a comment